SCA
VRTX icon

Sage Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Sage Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559K Buy
1,125
+13
+1% +$5.76K 0.12% 101
2026
Q1 		$496K Buy
1,112
+8
+0.7% +$3.73K 0.12% 96
2025
Q4 		$500K Buy
1,104
+53
+5% +$22.8K 0.12% 92
2025
Q3 		$411K Buy
1,051
+336
+47% +$140K 0.1% 104
2025
Q2 		$318K Buy
715
+114
+19% +$52.5K 0.08% 118
2025
Q1 		$291K Buy
601
+48
+9% +$22.4K 0.08% 121
2024
Q4 		$223K Hold
553
– – 0.06% 131
2024
Q3 		$257K Hold
553
– – 0.07% 125
2024
Q2 		$259K Buy
553
+30
+6% +$13K 0.07% 126
2024
Q1 		$219K Hold
523
– – 0.06% 130
2023
Q4 		$213K Buy
+523
New +$193K 0.07% 126

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Sage Capital Advisors's VRTX Position: Q2 2026 in Review

Sage Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q2 2026, buying an estimated $5.76K and bringing the position to 1,125 shares worth $559K. The position accounts for 0.12% of the portfolio, ranked #101.

Sage Capital Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sage Capital Advisors held 1,125 shares of Vertex Pharmaceuticals worth $559K as of Q2 2026.
  • Sage Capital Advisors bought 13 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.76K.
  • Vertex Pharmaceuticals made up 0.12% of Sage Capital Advisors's portfolio in Q2 2026, its #101 holding.
  • Sage Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sage Capital Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.